Phosphatidylserine GRAS Scope Review for U.S. Functional Food Brands

U.S. product teams sometimes find a phosphatidylserine entry in FDA’s GRAS Notice Inventory and treat it as a broad approval for “PS.” That is not how the evidence works. GRAS status concerns a defined substance under defined intended conditions of use, and FDA’s response belongs to the notice it reviewed.

The direct answer is: compare the proposed commercial PS and food use with the complete identity and conditions described in the relevant GRAS basis. Match source, manufacturing process, composition, specifications, impurities, food categories, use levels, serving assumptions, and cumulative intake. Read FDA’s response accurately. A “no questions” letter is not a transferable product approval, while “ceased to evaluate” is not a no-questions conclusion.

This guide supports conventional-food projects using phosphatidylserine, soy PS, or sunflower PS. It is not a GRAS conclusion for any Nutranexa product and not legal advice. The responsible U.S. food company should obtain qualified review for the exact ingredient and intended use.

The Short Answer: GRAS Is About Conditions of Use

Under sections 201(s) and 409 of the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations, an intentionally added food substance generally requires food-additive authorization unless its use is GRAS or another exception applies. FDA explains that scientific-procedure GRAS conclusions require the same quantity and quality of scientific evidence as food-additive approval, plus general recognition among qualified experts.

The safety conclusion is limited to the intended conditions of use. Therefore, a buyer should not ask only, “Is PS GRAS?” The useful question is:

Is this specific PS, made and controlled this way, generally recognized as safe for these food categories, at these use levels and resulting intakes?

FDA’s inventory contains several PS notices with different sources, specifications, uses, and outcomes. That history is valuable evidence, but it must be read notice by notice.

GRAS Notice Outcomes: Use the Right Language

FDA describes three general response categories:

1. The agency does not question the basis for the notifier’s GRAS conclusion.
2. The agency concludes that the notice does not provide a sufficient basis for a GRAS conclusion.
3. At the notifier’s request, FDA ceases to evaluate the notice.

Only the first is commonly called a “no questions” response. Even then, FDA is responding to the notifier’s conclusion for the substance and uses described; it is not approving every commercial product sold under the same ingredient name.

Do not write:

• “FDA approved phosphatidylserine”
• “all soy PS is FDA GRAS”
• “sunflower PS is automatically covered”
• “ceased to evaluate means accepted”

Use accurate internal language that identifies the notice number, substance, intended uses, response, and date.

An Eight-Part Scope Comparison

1. Substance identity and source

Compare:

• common or trade description
• soy, sunflower, marine, or other source
• lecithin starting material
• chemical and compositional profile
• physical form and carrier
• relevant identifiers

FDA’s inventory illustrates the issue. GRN 186 concerns soy lecithin enzymatically modified to have increased phosphatidylserine. GRN 223 concerns phosphatidylserine with listed conventional-food uses. Other notices address sunflower or marine sources. These are not interchangeable labels.

If the commercial product is sunflower-source, a soy-source notice may be part of the scientific background but does not eliminate the need to compare source-specific identity and safety information.

2. Manufacturing process

Review the process described in the notice or independent GRAS dossier:

• starting materials
• enzymatic or conversion steps
• solvents or processing aids where relevant
• purification
• drying and blending
• carrier addition
• controls for by-products and contaminants

Then compare the proposed supplier’s process at a level sufficient to identify material differences. FDA guidance addresses how significant manufacturing changes can affect the safety and regulatory status of food ingredients. A process difference is not automatically disqualifying, but it must be evaluated rather than ignored.

3. Composition and specifications

Build a side-by-side table for:

• PS content and calculation basis
• related phospholipid profile where relevant
• carrier or matrix
• moisture and stability-related attributes
• residuals, contaminants, and microbiological limits
• test methods and acceptance criteria

A headline “20%,” “50%,” or another assay does not establish equivalence. Two products can share a target PS content while differing in source, phospholipid composition, carrier, impurities, or process.

Use the supplier’s current specification and available COA evidence. Do not rely on an undated marketing sheet.

4. Intended food categories

List every proposed conventional-food category and compare it with the notice or other GRAS basis. FDA inventory entries can specify categories such as dairy products, dairy analogs, bars, cereals, or fruit-flavored drinks, with notice-specific descriptions.

Do not expand “food in general” or a category name without reading exclusions, qualifications, and the underlying dossier. Confirm whether meat, poultry, infant formula, medical foods, or other specialised categories are excluded, separately regulated, or outside the intended use.

A product may also need food-standard, labeling, or identity compliance beyond GRAS.

5. Use level and serving basis

Compare the proposed amount:

• per serving
• per reference amount or food quantity where relevant
• maximum use level in formulation
• expected servings per day
• target populations

Do not confuse the percentage of PS in the ingredient powder with the amount of PS delivered by the finished food. Calculate both the commercial ingredient addition and resulting PS amount.

If the brand proposes a higher level or a new category, the previous notice does not automatically cover it.

6. Estimated dietary intake

Safety evaluation considers exposure from intended uses. Build an intake model that reflects all proposed categories, use levels, consumption assumptions, and background sources where relevant.

Compare:

• mean and high-consumer estimates
• target population
• body-weight assumptions where used
• cumulative exposure across categories
• sensitive or excluded populations
• ingredient constituents that drive safety

Do not use a single serving as the complete exposure assessment when consumers may obtain PS from several foods.

7. Safety narrative and publicly available evidence

General recognition requires more than confidential supplier data. Review the scientific basis, publicly available information, expert reasoning, and any new evidence since the notice.

The company relying on a GRAS conclusion should be able to explain why the totality of evidence supports safety under its intended use. A supplier statement reading “GRAS” is not that explanation.

Check whether:

• cited studies match the substance and source
• exposure remains within the evaluated conditions
• new adverse information changes the conclusion
• differences from the reference material are scientifically addressed
• qualified experts would generally recognize the safety basis

Avoid medical efficacy claims. GRAS addresses safety of food use, not treatment benefits.

8. FDA response and current regulatory status

Retain the inventory page, releasable notice, amendments, and FDA response. Record:

• GRN number
• notifier
• substance
• filing and closure dates
• intended use
• response category
• relevant qualifications

Search current FDA databases and enforcement information before launch. A historical no-questions letter is evidence, but current law, product identity, manufacturing, and use still need review.

Can a Buyer Rely on Another Notifier’s GRAS Notice?

Public GRAS notices can support a company’s analysis, but a no-questions letter is addressed to the notifier and its described conclusion. A different company should not claim that FDA reviewed its product.

The practical options may include:

• demonstrate that the commercial substance and uses fall within an existing, well-supported GRAS conclusion
• develop an independent GRAS conclusion for the exact product and uses
• submit a GRAS notice to FDA
• use another lawful regulatory route where applicable

Selection requires qualified regulatory and scientific advice. The supplier can provide identity, process, specification, and quality evidence, but the finished-food company owns its formulation, intake, label, and market decision.

GRAS Scope Matrix

Use a Cross-Functional Launch Gate

GRAS scope should be reviewed before the formula, label, and purchase contract become difficult to change. Create a launch gate with named owners from R&D, regulatory, quality, procurement, and legal or external scientific support where appropriate.

R&D should freeze the proposed food categories, serving sizes, addition levels, and resulting PS amounts. Procurement should identify the exact source, supplier, grade, site, and specification. Quality should confirm that commercial controls and test methods match the substance described in the safety basis. Regulatory should compare intended conditions of use, cumulative intake, labeling, and FDA response language. The final decision owner should document the lawful basis relied upon.

Set explicit outcomes:

• Proceed: the commercial substance and every intended use fit the documented conclusion.
• Proceed with controls: the conclusion is supportable only with stated source, specification, use-level, population, or change restrictions.
• Hold for evidence: identity, process, intake, or safety information is incomplete.
• Select another route: the proposed use is outside the evidence and needs an independent conclusion, notification, food-additive authorization, reformulation, or other qualified strategy.

Carry the decision into the bill of materials and change-control system. A later source, carrier, process, specification, serving, or food-category change should return to the gate. This prevents a valid review for one beverage or bar from being copied into a materially different product launch.

Need a Source-Specific PS Document Set?

Share the proposed food category, serving, PS amount, source preference, annual demand, and GRAS comparison fields with Nutranexa. Request the current product specification, available COA evidence, source and process description appropriate for review, packaging, and manufacturing-support information. Nutranexa’s stated PS MOQ is 25 kg and standard bulk pack is 25 kg net per drum. Contato de vendas to define the product file; no supplier document by itself makes the finished use GRAS.

Common GRAS Review Mistakes

1. Calling an FDA no-questions letter an ingredient approval.
2. Treating all PS sources and grades as equivalent.
3. Comparing only the PS assay and ignoring process, carrier, and impurity profile.
4. Extending listed food categories or use levels without evaluation.
5. Ignoring cumulative intake across several foods.
6. Treating a ceased-to-evaluate notice as a favorable response.
7. Using a dietary-supplement NDI analysis as the conventional-food GRAS basis.
8. Repeating “self-GRAS” without a documented scientific conclusion.
9. Turning safety evidence into a disease or efficacy claim.

How Verified Nutranexa Facts Fit the Review

Nutranexa was founded in 2013, operates a 110,000+ m2 campus, and focuses exports primarily on Europe and North America. It provides separate product paths for general PS, soy PS, and sunflower PS, along with available specification and COA evidence, manufacturing and quality information, packaging and dispatch imagery, and R&D cooperation.

These facts help buyers define the commercial substance and request evidence. They do not establish FDA approval, a no-questions response for a Nutranexa product, equivalence to a particular GRAS notice, or safety under a finished-food use. The buyer must complete the source-, product-, and use-specific comparison.

Fontes

• FDA: Generally Recognized as Safe overview
• FDA: About the GRAS Notification Program
• FDA GRAS Notice Inventory
• FDA GRN 186: Soy lecithin enzymatically modified to have increased phosphatidylserine
• FDA GRN 223: Phosphatidylserine
• eCFR: 21 CFR 170.30, eligibility for GRAS classification

Perguntas frequentes

Does an FDA no-questions letter mean FDA approved the PS product?

No. FDA states that it does not question the notifier’s GRAS conclusion for the substance and conditions described. The letter is not a general product approval and should not be represented that way.

Can sunflower PS rely on a soy PS GRAS notice?

The soy notice may contribute scientific context, but source, composition, manufacture, specifications, and safety evidence must be compared. Source equivalence should not be assumed.

Is a GRAS conclusion needed for dietary-supplement use?

GRAS is a food-additive framework for substances added to food. Dietary supplements have their own ingredient and NDI considerations. A conventional-food project and a supplement project should follow their respective regulatory analyses.

What does “FDA ceased to evaluate” mean?

It means FDA stopped its evaluation at the notifier’s request. It is not the same as a no-questions response and should not be cited as FDA acceptance of the conclusion.

Can a supplier’s “GRAS statement” close the buyer review?

No. The buyer needs the underlying identity, process, specification, intended-use, intake, and safety basis and must determine how it applies to the actual product and finished-food use.

Conclusion

A responsible PS GRAS review is a scope comparison, not a database keyword search. Match the exact substance, manufacturing, composition, specifications, foods, levels, and cumulative intake; then describe FDA’s response accurately and document the scientific conclusion.

When the proposed product or use sits outside the evidence, pause the launch and choose an appropriate regulatory path rather than stretching a historical notice beyond its conditions.

Contato de vendas

Evaluating soy or sunflower phosphatidylserine for a U.S. conventional food? Contact Nutranexa Sales to request the current source-specific specification, available COA evidence, packaging information, and manufacturing-support documents for your GRAS scope review.

Próximas etapas recomendadas

• Revise o Phosphatidylserine página do produto.
• Comparar Soy PS e Sunflower PS.
• Verifique prova de fabricação e Qualidade e P&D.